Purpose To assess the effect of diagnostic mydriasis with 1% cyclopentolate on the intraocular pressure (IOP) of patients attending glaucoma, medical retina and cataract clinics. Methods Levels of ...

Vindesine (VDS), one of the vinca alkaloids, is widely used as an antineoplastic agent. Possible target sites are microtubules and tubulins in cancer cells. As the adverse effects of VDS, ...

Credit: Shutterstock. Ryzumvi is a preservation-free eye drop formulation of phentolamine mesylate, an alpha adrenergic blocker. The Food and Drug Administration (FDA) has approved Ryzumvi™ ...

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Mydriasis - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. The 'Mydriasis ...

Credit: Getty Images. MydCombi is a combination of tropicamide, an anticholinergic, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist. The Food and Drug Administration (FDA) has ...

FARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small ...

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Mydriasis - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. The 'Mydriasis ...

Please provide your email address to receive an email when new articles are posted on . In a second phase 3 registration trial, Nyxol helped reverse pharmacologically induced mydriasis at 90 minutes, ...

Please provide your email address to receive an email when new articles are posted on . Three years ago, tragedy struck my family with the loss of my brother due to metastatic lung cancer. My brother ...

First-in-class fixed combination mydriatic agent demonstrated robust efficacy, good tolerability in confirmatory MIST-2 Study NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), ...

NEW YORK--(BUSINESS WIRE)-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company with Phase 3 programs in presbyopia, myopia and mydriasis, today announced that it has ...

Data Bridge Market Research conducted a recent market intelligence study, thoroughly analyzing the Mydriasis Market. The newly published report employs an appealing layout that presents essential data ...